Pretreatment with the unlabeled precursor significantly decreased the uptake in A549/CXCR4 tumor (2.08 ± 0.36 vs. 1.11 ± 0.19%ID/mL, P < 0.01). This evidence concerns the gene CXCR4 and neoplasm.